739070 tn?1338603402

For those on Tysabri...

Below is a portion of the abstract issue by the New England Journal of Medicine.  I only highlighted the total number of cases of PML and the background of some those patients.....


As of February 29, 2012, there were 212 confirmed cases of PML among 99,571 patients treated with natalizumab (2.1 cases per 1000 patients). All 54 patients with PML for whom samples were available before the diagnosis were positive for anti–JC virus antibodies. When the risk of PML was stratified according to three risk factors, the risk of PML was lowest among the patients who were negative for anti–JC virus antibodies, with the incidence estimated to be 0.09 cases or less per 1000 patients (95% confidence interval [CI], 0 to 0.48). Patients who were positive for anti–JC virus antibodies, had taken immunosuppressants before the initiation of natalizumab therapy, and had received 25 to 48 months of natalizumab treatment had the highest estimated risk (incidence, 11.1 cases per 1000 patients [95% CI, 8.3 to 14.5]).

Positive status with respect to anti–JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct levels of PML risk in natalizumab-treated patients with multiple sclerosis. (Funded by Biogen Idec and Elan Pharmaceuticals.)

4 Responses
Sort by: Helpful Oldest Newest
572651 tn?1530999357
This was an interesting report - it was also reported via MedLine in perhaps an easier format to understand ----


"Study Shows MS Patients at Most Risk for Drug-Linked Brain Illness

Small number of Tysabri users develop rare but potentially fatal infection

Multiple Sclerosis

WEDNESDAY, May 16 (HealthDay News) -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri (natalizumab).

Even the multiple sclerosis patients at highest risk of developing the brain infection face low odds of getting it while on Tysabri, but the infection can be deadly.

"Now we can identify which risk group each patient is in. This will help doctors and patients make better decisions," said Dr. Gary Bloomgren, lead author of a study released Wednesday and vice president of drug safety at Biogen Idec, which makes the drug.

About 100,000 patients have taken Tysabri at least once. The drug, which is used mainly to delay the progression of multiple sclerosis, has been on the market since 2006. It originally went on the market in 2005 but was removed due to medical problems that some patients encountered, Bloomgren said.

Tysabri is expensive, costing about $40,000 a year. It dampens the immune system, potentially reducing the inflammation that is a major part of multiple sclerosis. Dampening the immune system, however, can allow an infection known as the JC virus to wreak havoc on the brain and cause a condition called progressive multifocal leukoencephalopathy.

The JC virus is extremely common, affecting about half of adults by middle age, but the immune system normally keeps it under control so it causes no symptoms. If unleashed, however, progressive multifocal leukoencephalopathy can cause cognitive problems, such as unusual behavior, paralysis and problems with vision, speech and balance, said study co-author Dr. Sandra Richman, senior medical director at Biogen Idec.

Once the symptoms appear, doctors usually advise patients to stop the treatment, she said. Progressive multifocal leukoencephalopathy often causes permanent disability, and can be deadly.

In 2010, the U.S Food and Drug Administration added a new warning about the rare brain infection to Tysabri's label. The drug also is used to treat Crohn's disease.

In January, the FDA approved a test to determine the risk of brain infection in Tysabri users.

In the new study, the researchers examined various statistics to figure out which multiple sclerosis patients were at highest risk of progressive multifocal leukoencephalopathy if they take Tysabri. Blood samples of nearly 5,900 patients with multiple sclerosis were analyzed.

Just more than 1 percent of patients showed signs of exposure to the JC virus, had taken immune-suppressing drugs before Tysabri and had been on Tysabri for 25 to 48 months.

The risk for those who hadn't been exposed to the JC virus was 120 times smaller at 0.009 percent.

Patients who worry about progressive multifocal leukoencephalopathy "may think about it differently because of the low risk in that subgroup of patients," Bloomgren said.

Multiple sclerosis patients who have been exposed to the JC virus but haven't taken immune-suppressing drugs while on Tysabri may choose to continue taking the drug, said Dr. Scott Zamvil, a professor of neurology at the University of California-San Francisco.

"Patients who are on the drug don't want to come off because it's that potent of a drug," he said. "It is the most potent of the currently approved drugs."

Patients need to talk to their physicians and weigh the benefit of the medication versus the potential risk, Zamvil said.

The study appears in the May 17 issue of the New England Journal of Medicine.

SOURCES: Gary Bloomgren, M.D., vice president of drug safety, and Sandra Richman, M.D., senior medical director, Biogen Idec, Cambridge, Mass.; Scott Zamvil, M.D., professor of neurology, University of California-San Francisco; May 17, 2012, New England Journal of Medicine"
Helpful - 0
1831849 tn?1383228392
I saw both this morning and agree that the MedPage version was a little closer to lay person speak :-)

If I read it correctly, you have about a 1% chance of developing PML if you are JCV positive AND took immuno suppressants prior to Tysabri AND have taken Tysabri for between 25 - 48 months.

If you start missing any of these benchmarks the 1% chance begins to get smaller. In my case, I'm JCV negative, have taken no other immuno suppressants and have taken Tysabri for 6 months. My chances of developing PML are 0.009%.

The other way to read this may be that even if you have taken immuno suppressants prior to Tysabri AND have taken Tysabri for between 25 - 48 months but are JCV negative your chances of developing PML are 0.009%.

In either case I think I'm OK :-)

Helpful - 0
572651 tn?1530999357
I agree, Kyle.  I'm good with being JC Negative, but I think I would also be liking those other odds. I'm pleased with the Tysabri, so far.
Helpful - 0
738075 tn?1330575844
I love my Ty, and I'm sooo grateful I'm JC negative.  Thanks for the link!
Helpful - 0
Have an Answer?

You are reading content posted in the Multiple Sclerosis Community

Top Neurology Answerers
987762 tn?1331027953
5265383 tn?1483808356
1756321 tn?1547095325
Queensland, Australia
1780921 tn?1499301793
Queen Creek, AZ
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Popular Resources
Find out how beta-blocker eye drops show promising results for acute migraine relief.
In this special Missouri Medicine report, doctors examine advances in diagnosis and treatment of this devastating and costly neurodegenerative disease.
Here are 12 simple – and fun! – ways to boost your brainpower.
Discover some of the causes of dizziness and how to treat it.
Discover the common causes of headaches and how to treat headache pain.
Two of the largest studies on Alzheimer’s have yielded new clues about the disease